Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770
- 1 June 2001
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 11 (12) , 1557-1560
- https://doi.org/10.1016/s0960-894x(01)00032-4
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Biaryl Ether Retrohydroxamates as Potent, Long-lived, Orally Bioavailable MMP InhibitorsBioorganic & Medicinal Chemistry Letters, 2001
- Marimastat (BB2516): Current status of developmentCancer Chemotherapy and Pharmacology, 1999
- Matrix metalloproteinases in angiogenesis: a moving target for therapeutic interventionJournal of Clinical Investigation, 1999
- Broad spectrum matrix metalloproteinase inhibitors: An examination of succinamide hydroxamate inhibitors with P1 Cα gem-disubstitutionBioorganic & Medicinal Chemistry Letters, 1998
- Discovery of Potent Nonpeptide Inhibitors of Stromelysin Using SAR by NMRJournal of the American Chemical Society, 1997
- Asymmetric synthesis of (R)-N-3-butyn-2-yl-N-hydroxyurea, a key intermediate for 5-lipoxygenase inhibitorsTetrahedron: Asymmetry, 1996
- New synthesis of isoxazolidinesJournal of Heterocyclic Chemistry, 1996
- Inhibition of the metastatic spread and growth of B16‐BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitorInternational Journal of Cancer, 1994